New drug combo shows promise for tough breast cancer
NCT ID NCT03568422
First seen Mar 28, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel for women with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at shrinking tumors or slowing the disease. About 37 participants will take part in two phases to find the best dose and measure response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.